| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
785.40(M) |
| Last
Volume: |
1,008,943 |
Avg
Vol: |
1,006,201 |
| 52
Week Range: |
$12.64 - $30.11 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cassava Sciences is a clinical-stage biotechnology company. Co. has combined technology with insights in neurobiology to develop solutions for Alzheimer's disease and other neurodegenerative diseases. Co. has two biopharmaceutical assets under development: its primary therapeutic product candidate, called simufilam, is a treatment for Alzheimer's disease; and its primary investigational diagnostic product candidate, called SavaDx, is a way to detect the existence of Alzheimer's disease from a small sample of blood.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
48,477 |
278,477 |
| Total Buy Value |
$0 |
$0 |
$831,428 |
$6,164,449 |
| Total People Bought |
0 |
0 |
2 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barbier Remi |
CEO and Chairman of Board |
• • • |
2010-06-02 |
4 |
AS |
$5.54 |
$78,053 |
D/D |
(14,089) |
6,129,685 |
|
- |
|
| Barbier Remi |
CEO and Chairman of Board |
• • • |
2010-06-01 |
4 |
AS |
$5.52 |
$152,644 |
D/D |
(27,673) |
6,143,774 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-05-27 |
4 |
AS |
$5.74 |
$63,019 |
D/D |
(10,979) |
48,187 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-05-27 |
4 |
OE |
$5.25 |
$57,640 |
D/D |
10,979 |
59,166 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-05-19 |
4 |
AS |
$5.77 |
$14,344 |
D/D |
(2,486) |
48,187 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-05-19 |
4 |
OE |
$5.25 |
$13,052 |
D/D |
2,486 |
50,673 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-05-18 |
4 |
AS |
$5.78 |
$45,812 |
D/D |
(7,926) |
48,187 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-05-18 |
4 |
OE |
$5.25 |
$41,612 |
D/D |
7,926 |
61,222 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-05-17 |
4 |
AS |
$5.75 |
$29,377 |
D/D |
(5,109) |
5,611 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-05-17 |
4 |
OE |
$4.40 |
$25,547 |
D/D |
5,109 |
53,296 |
|
- |
|
| Barbier Remi |
CEO and Chairman of BOD |
• • • |
2010-05-06 |
4 |
AS |
$5.61 |
$36,885 |
D/D |
(6,576) |
6,171,447 |
|
- |
|
| Barbier Remi |
CEO and Chairman of BOD |
• • • |
2010-05-05 |
4 |
AS |
$5.76 |
$115,776 |
D/D |
(20,100) |
6,178,023 |
|
- |
|
| Friedmann Nadav |
Chief Operating Officer |
• • – |
2010-05-04 |
4 |
AS |
$5.95 |
$89,205 |
D/D |
(15,000) |
275,951 |
|
- |
|
| Barbier Remi |
CEO and Chairman of BOD |
• • • |
2010-05-04 |
4 |
AS |
$5.94 |
$67,727 |
D/D |
(11,400) |
6,198,123 |
|
- |
|
| Roddy Peter S |
Chief Financial Officer |
• – – |
2010-05-03 |
4/A |
A |
$3.77 |
$15,016 |
D/D |
3,983 |
42,396 |
|
- |
|
| Friedmann Nadav |
Chief Operating Officer |
• • – |
2010-05-03 |
4 |
A |
$3.77 |
$14,160 |
D/D |
3,756 |
290,951 |
|
- |
|
| Barbier Remi |
CEO and Chairman of BOD |
• • • |
2010-05-03 |
4 |
AS |
$6.14 |
$73,178 |
D/D |
(11,924) |
6,209,523 |
|
- |
|
| Roddy Peter S |
CFO |
• – – |
2010-05-01 |
4 |
B |
$3.77 |
$15,016 |
D/D |
3,983 |
42,396 |
2.74 |
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-04-16 |
4 |
AS |
$6.29 |
$166,685 |
D/D |
(26,500) |
48,187 |
|
- |
|
| Schoenhard Grant |
Chief Scientific Officer |
• – – |
2010-04-16 |
4 |
OE |
$4.40 |
$137,850 |
D/D |
26,500 |
74,687 |
|
- |
|
| Barbier Remi |
CEO and Chairman of Board |
• • • |
2010-04-07 |
4 |
AS |
$6.23 |
$36,128 |
D/D |
(5,800) |
6,221,447 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-04-06 |
4 |
AS |
$6.29 |
$139,660 |
D/D |
(22,200) |
6,227,247 |
|
- |
|
| Barbier Remi |
CEO & Chairman of the Board |
• • • |
2010-04-05 |
4 |
AS |
$6.16 |
$61,580 |
D/D |
(10,000) |
6,249,447 |
|
- |
|
| Friedmann Nadav |
COO |
• • – |
2010-04-01 |
4 |
AS |
$6.17 |
$92,595 |
D/D |
(15,000) |
287,195 |
|
- |
|
| Barbier Remi |
CEO and Chairman of the Board |
• • • |
2010-04-01 |
4 |
AS |
$6.16 |
$73,896 |
D/D |
(12,000) |
6,259,447 |
|
- |
|
504 Records found
|
|
Page 8 of 21 |
|
|
0.31 (1.55%) 
